IL33 and graft versus host disease: Nonhematopoietic cells of the intestine are major sources of IL–33 in both clinical GVHD and experimental models, and the absence of IL-33 dramatically suppresses TNF-α in the serum and reduces GVHD severity in experimental models of alloHCT.